Sunday, May 5, 2024
5/5/2024
Abstract Neuroimmune signals regulate neuronal function and survival. We have strong evidence indicating that activation of the heterodimeric interleukin-13 receptor alpha 1/interleukin-4 receptor alpha (IL-13Ra1/IL-4Ra) complex in midbrain dopaminergic (DA) neurons affects their viability. In the brain, IL-13Ra1/IL-4Ra is uniquely expressed on the neurons of the substantia nigra pars compacta (SNc) that are lost in Parkinson’s disease (PD). We also showed that interleukin 13 (IL-13), produced during neuroinflammation by microglia and neurons, can modulate the activity of dopaminergic cells and increase their susceptibility to oxidative damage. To date, there is a gap in understanding how neuroinflammation contributes to the selective loss of DA neurons in PD. Having established that activation of IL-13Ra1 signaling can affect the survival of dopaminergic neurons during neuroinflammation, in the present application we wish to address this gap. Specifically, we wish to test the hypothesis that IL-13 and neuronal IL-13Ra1 cause damage by stimulating a regulated cell death pathway called ferroptosis. We also wish to determine to what extent IL-13 and IL-13Ra1 contribute to neurodegeneration in a mouse model of alpha- synucleinopathy (a-Syn), a hallmark trait of PD that is associated with neuroinflammation and oxidative damage. This will help us determine whether targeting IL-13Ra1 signaling might be a viable approach to slow neurodegeneration in humans affected by a-synucleinopathy such as PD. The ability of ruxolitinib, an FDA- approved drug that inhibits IL-13Ra1 signaling and that of the novel ferroptosis inhibitor CMS121, to reduce IL- 13-mediated damage in vivo will also be tested. Finally, we propose in vivo experiments un a novel mouse model to test the hypothesis that a rare genetic variant of IL-13 found in individuals diagnosed with early-onset PD can contribute to more rapid loss of dopaminergic neurons in a mouse with the homologue of this mutation. If successful, these experiments will provide strong support for the hypothesis that IL-13 and IL-13Ra1 are novel targets for preventing PD or slowing its progression, at least in a sub-set of PD patients.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
